

Utilization of Infertility Treatments: The Effects of Insurance Mandates[⊗]

Marianne Bitler
University of California-Irvine, RAND Corporation, and NBER

Lucie Schmidt
Williams College

June 2010

[⊗] Bitler gratefully acknowledges financial support from the National Institute of Child Health and Human Development (NICHD) (R03 HD046485). Schmidt gratefully acknowledges financial support from NICHD (R03 HD047544). All errors or omissions are our own. We thank Tom Buchmueller, Kitt Carpenter, Stacy Dickert-Conlin, Tracy Gordon, Steven Haider, Mireille Jacobson, Darius Lakdawalla, Purvi Sevak, Kosali Simon, two anonymous referees and seminar participants at Michigan State University and the Center for Studies in Demography and Ecology at the University of Washington for helpful comments, and Chris Rogers and Anjani Chandra for their generous assistance with the NSFG data. Corresponding author: Lucie Schmidt, Department of Economics, Schapiro Hall, Williams College, Williamstown, MA 01267, email: lschmidt@williams.edu, phone (413) 597-3143; fax (413) 597-4045.

Utilization of Infertility Treatments: The Effects of Insurance Mandates

Abstract

Over the last several decades, both delay of childbearing and fertility problems have become increasingly common among women in developed countries. At the same time, technological changes have made many more options available to individuals experiencing fertility problems. However, these technologies are expensive, and only 25% of health insurance plans in the United States cover infertility treatment. As a result of these high costs, legislation has been passed in 15 states that mandates insurance coverage of infertility treatment in private insurance plans. In this paper, we examine whether mandated insurance coverage for infertility treatment affects utilization. We allow utilization effects to differ by age and education, since previous research suggests that older, more educated women should be more likely to be directly affected by the mandates than younger women and less educated women, both because they are at higher risk of fertility problems and because they are more likely to have private health insurance which is subject to the mandate. We find robust evidence that the mandates do have a significant effect on utilization for older, more educated women that is larger than the effects found for other groups. These effects are largest for the use of ovulation-inducing drugs and artificial insemination.

I. Introduction

Over the last several decades, delay of childbearing among women in developed countries has become increasingly common. At the same time, the number and share of women experiencing fertility problems have also increased. In 2002, fertility problems affected 7.9 million women in the United States, and the rate of such problems among women 15–44 had increased 44% since 1982 (Chandra and Stephen, 2005). Technological changes have made many more options available to individuals experiencing fertility problems. These advances have enabled many women to conceive and deliver their own biological children. However, these technologies are expensive, and only 25% of health care plans in the United States cover infertility treatment (William M. Mercer, 1997).¹

As a result of these high costs, legislation has been introduced at both the federal and state levels that would mandate coverage of infertility treatment by private insurers. As of 2010, fifteen states have enacted some form of infertility insurance mandate, and additional states have ongoing legislative advocacy efforts in this area. Much of the rhetoric from supporters surrounding passage of the mandates focuses on expanding access to those who would not be able to afford treatment otherwise.² On the other hand, opponents argue that these mandates and other health insurance regulations force insurers to offer benefits for services that people might not want or be able to afford, suggesting that mandates like these may not lead to increases in utilization, and perhaps might have other adverse effects. Given the continued interest in these

¹ While not all fertility treatments are expensive, in general the less expensive treatments are more likely to be covered by health insurance in the absence of mandates, in part because some of them can legitimately be billed under categories covered by most insurance plans.

² For example, RESOLVE, the national infertility organization, says on their website “RESOLVE endorses state and federal legislation that will require insurers to cover the costs of appropriate medical treatment. RESOLVE believes the option to pursue medical treatment for infertility must be available to all those who need treatment, not solely those with the resources to pay for the treatment out of pocket” (www.resolve.org). In an article about the passage of the New Jersey mandate in 2001, State Senator Diane B. Allen, a sponsor of the bill, was quoted as saying “[C]ouples who are infertile and can’t afford these things on their own have been treated extremely unfairly” (*New York Times*, 2001).

types of mandates by policy-makers as well as the current focus on health care reform, understanding whether these types of private insurance market regulations affect utilization of health care services, and if so, for whom, is critical.³

In this paper, we use data from the National Survey of Family Growth (NSFG) to examine whether infertility insurance mandates affect utilization. We allow utilization effects to differ by age and education, since previous research suggests that older, more educated women should be more likely to be directly affected by the mandates than younger women or less educated women, both because they are at higher risk of fertility problems and because they are more likely to have private health insurance which is subject to the mandate.

We contribute to the literature about fertility determinants, and in particular, infertility treatment in several ways. Our research uses panel data techniques, and our data span years both before and after the adoption of most mandates, allowing us to use variation in adoption timing across states and years, and to control for unobservable differences in utilization across states and over time using state and year fixed effects. This cannot be done in studies using clinic data reported to the Centers for Disease Control, since these data are unavailable for the years before most mandates were in effect. We can examine effects on the use of all infertility treatments, while the CDC data only examine the use of assisted reproductive technologies (ART) like in vitro fertilization (IVF), which comprise only a small fraction of infertility treatments received. Our data also allow analysis of a wide range of specific types of non-ART infertility treatments, including ovulation-inducing drugs, artificial insemination, and testing of both partners. Finally, we focus on the use of treatments at the population level, and can therefore produce estimates of the effect of mandates on the utilization of treatments by all women, not just those whose

³ A number of papers (Buckles, 2006; Schmidt, 2007; Bundorf et al., 2008; and Bitler, 2010) have illustrated an effect of these mandates on births or birth outcomes, suggesting that there is likely to be a utilization effect as well. We discuss these papers in detail in Section III.

treatments result in live births. This could be a substantial share of the additional treatments induced by the mandates.

We find robust evidence that the mandates have the largest effect on utilization of infertility treatment for highly educated, older women, and that these effects are statistically significant. By contrast, most of the impacts for other groups are smaller in magnitude and insignificant. In addition, the pattern of results confirms expectations about the types of treatments that should be impacted: relatively expensive treatments that would be more difficult to pay for out of pocket and would not be covered unless infertility treatment was covered. Specifically, we find that mandates lead to statistically significant and relatively large increases in the use of ovulation-inducing drugs, and in some specifications in the use of artificial insemination. These results suggest that private insurance regulations requiring that insurers cover specific treatments have the ability to alter utilization in the context of infertility treatment.

II. Mandated Insurance Benefits

Over the past 30 years, state-level mandated health insurance benefits have grown in popularity as a means of trying to regulate the private health care system. Currently, well over 1,000 state mandated benefits are in effect (EBRI, 2005). These laws require the coverage of specific health services or coverage of the services provided by specific types of providers. Advocates of the laws appeal to unmet need, while opponents argue that such laws force firms to buy coverage for services their employees value less than their marginal cost, potentially leading to higher rates of uninsurance.

The primary economic efficiency argument in favor of mandated benefits for specific illnesses and conditions relies on asymmetric information between patients, insurers, and firms.

If such asymmetric information exists, this could lead to adverse selection in the health insurance market (e.g., Rothschild and Stiglitz, 1976). Mandates could also cause detrimental effects, if mandating benefits reduces employment or health insurance coverage.⁴ However, research on the effects of mandates on health insurance coverage (Gruber, 1994) and labor market outcomes (Kaestner and Simon, 2002) finds little effect overall.

Proponents of mandated insurance benefits aim to affect utilization of health services and, ultimately, health outcomes. However, recent evidence on the effects of mandates is mixed, suggesting that mandates may increase utilization for some groups, but have little impact on other outcomes. Bao and Sturm (2004) and Pacula and Sturm (2000) find no significant effects of mental health parity legislation (considered to be a “high-cost” mandate) on utilization of mental health services among the privately insured, but find some evidence that mandates increase utilization of services among those with poor mental health. Recent work on early postpartum discharge laws (Liu et al. 2004) finds a positive significant effect of these laws on length of hospital stays. Other work suggests that mandates for breast cancer screenings have led to a significant increase in annual mammography rates (Bitler and Carpenter, 2009).

Several possible explanations have been considered for the lack of consistent effects found in much of the existing literature. First, state-level mandated benefits will not affect all individuals within a state. Mandates only apply to individuals (and their covered dependents) who have private insurance, and should only affect individuals employed by firms which do not already cover such benefits. In addition, the Employment Retirement Income Security Act of 1974 (ERISA) preempts specific state regulation of self-funded insurance plans provided by private-sector employers. As such, it is possible that legislation may not affect enough individuals to discern an impact if looking at the entire population. For example, Liu et al.

⁴ Effects on health insurance coverage could result either from reduced offering of insurance or reduced take-up.

(2004) find that the effect of drive-through delivery laws has been blunted by ERISA.

Furthermore, many mandates potentially affect only a smaller subgroup of the population (for example, mental health mandates affect those in need of mental health services), and this may not be the same subgroup that has private insurance. Even if the subgroup consists of individuals who are privately insured at high rates, if they are a small share of the population or if the effect for them is small, it might be easy to conclude that the overall policy had little or no significant effect from regressions which constrain the policy to have the same effect for everyone.⁵

Second, it has been suggested that perhaps state mandate laws are not binding (Gruber 1994). Some evidence suggests that benefits are similar in firms in states that mandate relative to firms in states that do not mandate, as well as in firms that self-insure relative to firms that are fully-insured within mandate states (Gruber, 1994; Acs et al., 1996; and Jensen et al., 1998), although much of this evidence is dated or relies on employee rather than firm data. However, this is not usually the case for infertility treatment, which is rarely covered in the absence of mandates.

Firms may also manipulate the combination of benefits and wages they offer to attract or retain particular types of employees (e.g., Gelbach, Klick, and Wexler, forthcoming; Oyer, forthcoming). For example, if being an employee who values infertility treatment is positively correlated with productivity, then even self-insured firms may choose to offer their employees insurance coverage which includes infertility benefits. If mandates do not affect the benefits offered by firms, then they would not be expected to affect utilization of services or health outcomes unless they resulted in premium changes that altered take-up decisions. Finally, there

⁵ Intuitively, if the effect of the policy is small for the relevant group relative to the residual variance and zero (or close to zero) elsewhere, or if the subgroup is small, a test for an overall policy effect is more likely than a test for a policy effect which is subgroup specific to fail to reject a null of zero effect.

are political economy issues associated with the passage of mandates. If employers do not expect a mandate to have a large impact on health care utilization and costs, they are less likely to oppose the legislation (Bao and Sturm, 2004). Overall, the theoretical predictions and empirical findings from previous work are mixed; thus it is an empirical question whether infertility insurance mandates will have real effects on utilization of services.

III. Infertility Treatment and Infertility Insurance Mandates

In order to understand the potential effects of infertility insurance mandates, it is necessary to understand infertility and its treatment. Today, treatment for infertility tends to follow a hierarchical progression, although not all couples progress neatly through all stages of treatment. In general, the first stage of treatment is a diagnostic workup, involving a thorough examination of each partner's reproductive organs and their circulatory, endocrine, and neurologic functions. Couples who initiate treatment begin at Level I, which involves initial ovarian stimulation with clomiphene citrate for up to 6 cycles (taking at least 6 months). Level II involves the use of exogenous gonadotrophins (another drug used to stimulate ovulation), with or without intrauterine insemination (IUI), for up to 6 cycles, and Level III involves assisted reproductive technologies such as *in vitro* fertilization (IVF), for up to 4 or more cycles. As a result, many but not all couples who reach Level III will also have received Level I and II treatments along the way.⁶ Of couples who begin treatment, over 80% of those who proceed through all the steps are likely to conceive (Gleicher, 2000). Even for couples who are successful with their first cycle of IVF, the process can take 2–3 years.

⁶ This progression is also evident in our data from the National Survey of Family Growth. For example, of the women in the NSFG who reported receiving IVF, about 80% reported receiving male and female testing, 65% also received ovulation-inducing drugs, and 46% also reported artificial insemination. These and other numbers are reported in Table 2, and discussed in greater detail in Section IV.

Infertility services can be quite expensive and are not covered by many insurance plans. Hormone therapy can range from \$200–\$3,000 per cycle. Tubal surgery can range from \$10,000–\$15,000, requires a hospital stay, and poses a high risk of complication (RESOLVE, 2003). The average cost of an IVF cycle in the United States is \$12,400 (ASRM, 2003), and Neumann, Gharib, and Weinstein (1994) calculate that the cost per successful delivery through IVF ranged from \$44,000 to \$211,940 in 1992 dollars, depending on the cause of infertility, the mother's age, and other factors.

As a result of these high costs, one way in which access to infertility treatments has been expanded in the United States is through legislative action. The first state-level infertility insurance mandate was enacted by West Virginia in 1977. Since that time, fourteen other states have passed mandates, and additional states have ongoing legislative advocacy efforts in this area. Table 1 contains a list of states that have passed mandates, along with the year the mandate passed, and shows that there is considerable variation in both the timing of the mandates and in the types of states that have passed mandates; with the list including both small and large states, as well as states from all U.S. regions. Some mandates are mandates “to cover,” and require that health insurance companies provide coverage of infertility treatment as a benefit included in every policy. Less commonly, states have enacted mandates “to offer,” and require only that health insurance companies make available for purchase policies that cover infertility treatment. Finally, some mandates exclude coverage of IVF.⁷ While only fifteen states have mandates in place during our sample period, these mandates were enacted in a number of large states and therefore affect an increasingly large fraction of the population. In 1981, less than one percent of the population resided in a state affected by the mandates, compared to 47.2% in 2003.

⁷ For additional detail on the mandates, see Schmidt (2005).

Previous research has examined the impacts of these insurance mandates on fertility. Schmidt (2007) uses Vital Statistics Detail Natality Data (DND) and Census population counts to examine the effects of the mandates on first birth rates, and finds that mandates increase first birth rates among older women by 19 percent. Buckles (2006) uses the DND and finds that the insurance mandates have increased the number of children per birth. Bitler (2010) uses the DND and finds an increase in the probability that infants born to older mothers are twins, and a larger increase in the probability that they are mixed-sex twins. Bundorf et al. (2008) use the DND and provide evidence of an increase in deliveries and an increase in multiple births for older women. This previous literature has focused on older women in states with mandates, in part because they are more likely to be infertile and demand treatment and in part because any mandate effects operating through private insurance markets must affect women who are privately insured at high rates.⁸

These papers provide consistent evidence that the infertility mandates have had significant fertility effects for older women. This implies that the mandates have had utilization effects as well. However, examining these utilization effects directly is important for a number of reasons. First, it would allow confirmation of the previously discovered fertility effects with a different data source. More importantly, examining utilization effects could provide information on the types of treatment that women receive. Some treatments are relatively high cost, while others are less expensive. Some are more likely to be used by the women with the lowest fecundity (e.g., IVF) while others may be used more broadly. Some may legitimately be covered

⁸ An alternative possibility is that the mandates could have a larger impact for younger than older women (conditional on needing treatment), as older women are more likely to be higher income and therefore presumably have lower price elasticities of demand. Chambers et al. (2009) reports price elasticities of demand for IVF from developed countries, but does not calculate the elasticities by age or education. However, at the same time, younger women face a longer time frame before they become unable to have a child for biological reasons after menopause, and also may be less likely to be aware of their possible impaired fecundity. In addition, for two women with the same biological ability to have children at each age, the younger woman will still be less likely than older woman to have difficulty conceiving because of the age-related decline in fecundity.

by health insurance even if infertility treatment is excluded (e.g., tubal surgery). Mandates could also cause women to progress through the levels of treatment more quickly than they would if they faced expenses out of pocket. Answering these questions is an important step towards understanding the relevant costs and benefits of the insurance mandates. Finally, studying the effects of the mandates on utilization provides information on use of treatments that do not result in live births, which would be undetectable using birth records such as the Detailed Natality Data.⁹

The majority of the previous work on the impacts of the mandates on utilization of services has focused on a single measure of utilization — cycles of assisted reproductive technologies (ARTs) (e.g., Jain et al., 2002; Hamilton and McManus, 2004; Bundorf et al., 2008; Henne and Bundorf, 2008; Bundorf et al., 2009).¹⁰ ARTs include all procedures that combine egg and sperm outside the body, such as IVF. These papers use data from a combination of two sources: Congressionally mandated clinic reports of success rates for ART cycles, and reports of such treatments collected by the American Society for Reproductive Medicine (ASRM), a provider group. These papers find consistent evidence that mandates are associated with increased rates of IVF utilization. However, unfortunately these data have two important limitations. First, when these two data sources are combined, they only extend back to 1987 or so, a period after many of the mandates were enacted. These papers therefore cannot use pre-

⁹ Data on timing of the first fertility visit is only available for the 1995 and 2002 NSFGs. Fully 30% of all women who ever used ovulation-inducing drugs, 42 percent of women who used artificial insemination, and 54% of women who ever used IVF have never had a live birth. While some share of these women are likely still getting treatment and may go on to eventually have a live birth, others most likely have been unable to conceive or carry a live birth to term even with the help of treatment. This suggests that a large share of potential treatments might be missed in data that only looks at live births. If we limit this calculation to those women who had no first birth after their first infertility treatment and have not had a visit for infertility treatment in the past year, assuming that these women might be the most likely to have given up trying to conceive, we see that 15% of those getting any medical help to get pregnant, 16% of those who took ovulation-inducing drugs, and 20% of those getting insemination fall into this category.

¹⁰ One exception is a recent paper by Mookim et al. (2008). They use claims data from a set of large firms from 2001–2004 to look at a variety of treatment uses and their impact on outcomes. While they too capture a large set of treatments, as with the papers on use of ART, their data are from a post-mandate period for most states.

mandate data on utilization and therefore cannot control for unobserved differences in utilization across states that may be correlated with but not caused by the mandates. In addition, these studies must limit their analyses to ART procedures. Despite being very expensive, these ARTs comprise only 5% of all infertility treatments (ASRM, 2003). In our own NSFG data, only 2 percent of women who ever had any infertility treatment reported using IVF.

In earlier work, Bitler and Schmidt (2006) use the National Survey of Family Growth to examine racial, ethnic, and socioeconomic disparities in infertility and in utilization of infertility treatment. This paper finds that fertility problems are more likely among non-white and less-educated women, but that infertility treatment is utilized much more heavily by white and college-educated women. The paper then looks at the insurance mandates, and finds no evidence that they have mitigated these racial, ethnic, or socioeconomic disparities in utilization of infertility treatment. In fact, Bitler and Schmidt (2006) finds no effect of these mandates on utilization of infertility services for the overall population of women aged 15–44, or for a subgroup of college-educated women or older women or white women. They do report that a model with a three-way interaction between high education, any mandate, and age at least 30 leads to a statistically significant marginal effect on any use of infertility treatment or medical help to prevent miscarriage of 4.6 percentage points. However, this result is included only to bolster an argument about power for explaining disparities and not explored in any detail.

In this paper, we use the National Survey of Family Growth to comprehensively explore utilization effects of the infertility insurance mandates. The timing of the NSFG includes years spanning the passage of the infertility mandates, and therefore allows us to control for unobservable differences in utilization across years that are constant over time. We replicate the result of Bitler and Schmidt (2006) – that older, more-educated women exhibit an increase in

utilization as a result of the mandates. We then use the rich detail on types of infertility treatments available in the NSFG to examine the robustness of these findings. First, we look at whether mandates primarily affect use of medical help to get pregnant versus use of medical help to prevent miscarriage. Mandates should have a larger impact on the use of medical help to get pregnant, and should have only indirect effects on the use of medical help to prevent miscarriage, which were likely covered by existing insurance. These indirect effects could result if mandates induce greater use of treatments among women who after treatment become pregnant and then later miscarry. Then, we look at the association between the mandates and the use of specific treatments that are costly and might plausibly be affected by the mandates. The NSFG provides information on a wide set of possible treatments, so we are able to examine a wider range of specific infertility treatments than are available in most other data sets.

There are several reasons that older, highly-educated women should be particularly strongly affected by infertility mandates. The first is related to demand for treatment. In order to desire treatment for infertility, one has to seek to become pregnant and be unsuccessful.¹¹ Over the last several decades, increases in female labor force participation and educational attainment have been accompanied by delays in childbearing.¹² The average age at first birth has risen from 21 years in 1970 to 25 in 2000 (Mathews and Hamilton, 2002), and differences in age at first birth by educational category have been even more striking. College-educated women are more likely to delay, perhaps in part to reduce the motherhood wage penalty associated with childbearing (e.g., Blackburn et al., 1993; Miller, 2008). As women wait longer before

¹¹ Medically, one is defined to be infertile after one year of unsuccessful efforts to become pregnant if the woman is under 35, or six months of unsuccessful efforts if 35 or older.

¹² These delays in childbearing depend upon the ability of women to effectively control their fertility through contraception and or abortion (e.g.; Goldin and Katz, 2002; Bailey, 2006; Ananat, Gruber, and Levine, 2007; and Guldi, 2008).

attempting to have children, the age at which women's fertility problems are first discovered will rise.

In addition, according to the clinical and demographic literature, age is independently associated with difficulty conceiving and carrying a pregnancy to term (Menken, 1985; Weinstein et al., 1990). Older women are significantly more likely to experience fertility problems and to seek help for these problems (Stephen and Chandra, 2000; Wright, Schieve, Reynolds, and Jeng, 2003). For example, in 2002, women 30 and older accounted for almost 89% of all assisted reproductive technology procedures performed in the United States.

The second reason to expect any effects to be stronger among older, highly-educated women is that these state-level mandates generally only legally apply to persons with private health insurance.¹³ Our own estimates from 2003 Medical Expenditure Panel Survey data suggest that 14–19% of private sector employees enrolled in employer-provided insurance in the U.S. were in firms to which these infertility insurance mandates applied (firms with at least one non-self insured plan) (derived from AHRQ 2005). Older, highly-educated women are more likely to have private coverage (through their own employer, or a spouse's employer, or an individual plan) than are other women. During calendar year 2002, 85% of women 30 and older with some college were covered by a private health insurance plan, while only 64% of women with at most a high school degree had such coverage.^{14, 15} We expect the effects to be largest

¹³ However, since ERISA exempts self-insured plans, having private insurance is a necessary but not sufficient condition for having mandate affect one's coverage of infertility treatment. Unfortunately, no publicly available data allow us to test whether older, educated women are more likely than younger or less-educated women to have private insurance from a plan that does not self-insure. A recent article using firm based data suggests that about 50 percent of covered workers in 2001 were in plans that were self-insured, and that this number had declined slightly since 1993 (Gabel, Jensen, and Hawkins, 2003).

¹⁴ These numbers are derived from authors' tabulations from the 2003 March Current Population Survey.

¹⁵ This same group of women is also likely to have higher levels of income with which they could presumably pay for infertility treatments out of pocket. However, the median family income for white women with at least some college education in 2001 was approximately \$58,000, which likely would not easily enable a family to pay for infertility treatments out-of-pocket, given estimates that suggest that the median cost per live delivery resulting from

and relatively concentrated among this subgroup of older, highly-educated women in states with mandates. Mean reports of ever having had any medical help to get pregnant (reported in Table 3 and discussed below) support this prediction, with rates for older women with some college being 1.5 times as large as for older women with no college (0.168 versus 0.112) and 3.5 times as large as for younger women (with or without some college) (0.168 versus 0.048).

IV. Methodology and Data

We pool individual-level data from the 1982, 1988, 1995, and 2002 rounds of the NSFG to see whether utilization of infertility treatment is heavier in states with infertility insurance mandates. Each wave of the NSFG surveys a nationally representative sample of women aged 15–44 on their fertility and marital histories. The NSFG is the only nationally representative source of individual-level data that asks detailed questions on infertility treatment, and the only publicly available source of data that provides information on infertility treatments that do not involve ARTs.^{16,17} It allows us to examine changes in utilization of treatments that do not result in live births. In addition, it is the only data set with information on infertility treatments that spans the years both before and after the mandates were passed, which is essential when trying to control for unobservable state differences in treatment propensities. We use the restricted-access version of the NSFG data with state identifiers, and merge information on state infertility insurance mandates to the NSFG data.

IVF is \$56,419 (Collins, 2001). More recent estimates from a comparison of developed countries suggest that the gross cost of a single IVF cycle as a percent of annual disposable income was highest in the United States, at 50%, compared to 12% in Japan (Chambers et al., 2009).

¹⁶ Claims data such as that used by Mookim et al. 2008 also have data on various treatments, but only for women with insurance that reimburses them for it. As far as we know, such data are also not publicly available for a period pre-mandates.

¹⁷ In 2002, the NSFG asked male respondents about their use of infertility treatment for the first time. We do not analyze these data in this paper. However, Anderson et al. (2009) report that 7.5% of all sexually-experienced men in the 2002 NSFG reported a visit for help with having a child.

Our first dependent variable of interest for this analysis is an indicator for whether the woman has ever obtained infertility treatment. Women are coded in the NSFG as having ever obtained infertility treatment if they reported either having obtained medical help to get pregnant or having obtained medical help to avoid a miscarriage (or both). We first look at the aggregate variable, but we then break it out into the two components, since we expect insurance mandates to affect the two variables differently. If there are utilization responses that are clearly due to the mandates, we would expect them to affect use of medical help to get pregnant more than use of medical help to prevent miscarriage (which was likely to be covered in the absence of a mandate, and should only indirectly respond to the mandates).

We then decompose the “obtained any medical help to get pregnant” variable by *type* of treatment. Women were asked about various specific types of treatment-listed in the next sentence—as well as about some “other treatment”. Thus, this category includes some relatively costly therapies that are almost exclusively used for infertility treatment — ovulation-inducing drugs, artificial insemination, and IVF; but it also includes other medical procedures that are less expensive or might plausibly have been covered without mandates (these include testing of the respondent or her partner, surgery for blocked tubes, and “other treatment” (which varies by year of the survey but includes treatment for endometriosis or fibroids, advice, and “other treatment not listed” categories)). At least one of these other procedures, tubal surgery, is increasingly considered by the medical profession to be a less attractive substitute for IVF (Gocial, 1995; Practice Committee of the American Society of Reproductive Medicine, 2008). Other evidence suggests that even in the absence of insurance coverage for infertility treatment, some treatments may be paid for by insurers under alternate billing codes (Blackwell and Mercer, 2000; Jones and Allen, 2009). We expect the mandates to increase use of ovulation-inducing drugs, artificial

insemination, and IVF more than they increase use of the other therapies both because these are more expensive and because these are harder to surreptitiously bill for in the absence of insurance coverage for infertility treatment. However, it is likely that capturing effects on IVF will be challenging in a woman-based sample like the NSFG due to sample size – only 0.2 of a percent of the women in all waves of the NSFG report receiving *in vitro* fertilization.

As would be expected given the hierarchical nature of the typical treatment ladder discussed in Section III, many of these women are obtaining more than one treatment, and the NSFG allows women to check more than one treatment in their responses. This use of multiple treatments is reported in Table 2. Panel A of Table 2 shows the share of respondents who received each of the specific types of infertility treatments (Columns 1-6), or receiving some other treatment (Column 7), first out of all women, and then out of all women who received medical help to get pregnant. For women receiving the specific treatments listed in columns 1-6, Panel B reports the share also receiving the other treatments listed by row. For example, Column 1 indicates that among women who used ovulation-inducing drugs, 17% also had artificial insemination, 3% had IVF, 62% had the woman tested and 52% had the man tested, 18% had tubal surgery, and 69% had some other treatment. Among women who had artificial insemination, 10% had IVF, 71% ovulation-inducing drugs, 85% had the woman tested, 75% had the man tested, and 78% had some other treatment. The overlap of treatments suggests that we might observe increases among all treatments, even those which might plausibly have been paid for in part by insurance which did not include infertility treatment (e.g., see Blackwell and Mercer, 2000; Jones and Allen, 2009).

Given how common use of multiple treatments is in our sample, we wanted to isolate those who reported “any other treatment” but did not also receive one of the six treatments

specifically identified. To do this, we created an alternative residual “other treatment” variable for women who reported medical help to get pregnant but did not receive any of the treatments listed in Columns 1–6. Means for this residual “other treatment” variable are reported in column 8, and this residual “other treatment” is the one we report regression results for. Hypotheses about this second other treatment variable are the most clear – that reports of it should not go up significantly with the mandates.

One potential issue with the outcome measures used here relates to the distinction between stocks and flows. Conceptually, we would like to measure the effect of the mandates on the likelihood that a woman utilizes infertility treatment in a given year. However, the variables we are using examine whether the respondent has *ever* received infertility treatment, and therefore measure the stock of women who have received treatment. Use of a stock measure in state-year fixed effects design can lead to overstating the magnitude of the effect, with the magnitude of the overstatement increasing with the length of the post-treatment implementation reporting period. However, all of our variables are binary indicators of ever using particular treatments. If these mandates were only to increase the level of use (intensive margin) and had no effect on whether a woman ever used any treatment (the extensive margin), our binary indicator variables would not show an increase. Thus, even if mandates affect the number of women who receive treatment in a given year, the stock of women who have ever received treatment may be changing much more slowly. This suggests both that the true effects of the mandates on contemporaneous use of treatments may be larger than the estimates presented below, and that our power to find significant effects may be reduced. These two competing effects suggest that the direction of bias in the magnitude of our estimates could either be upward or downward. Despite these possible limitations, our analysis provides an important contribution

to the literature, since, as detailed in the previous section, it allows us to learn more about the extent to which these mandates affect use of all treatments (not simply ARTs), and uses an identification strategy that can control for unobservable differences across states in utilization.

Table 3 contains summary statistics for our treatment variables for all women, as well as broken out by age group (under 30 versus 30 and older) and by completed education (no college versus at least some college). While about 10% of women 15–44 have ever obtained medical help to get pregnant, this varies dramatically by age and educational status. Only about 5% of women under 30 have obtained such treatment, while 11.2% of women 30 and older with no college and 16.8% of women 30 and older with some college have obtained such treatment. These patterns hold for the aggregate “had treatment to help get pregnant” variable and virtually every individual type of infertility treatment. Older women with at least some college are 3.5 times as likely as women under 30 with some college to have received medical help to try to get pregnant (16.8% versus 4.8%). They are about five times as likely as younger women to have been treated with ovulation-inducing drugs (6.5% versus 1.4%), nine to nineteen times more likely to report artificial insemination (1.9% versus 0.1% or 0.2%), and twenty-four times more likely to report in vitro fertilization (0.49% versus 0.02%).¹⁸ The differences in use by education category among the older women are still large, although not as dramatic as the differences discussed above. Older women with more education were 1.9 times as likely as older women with less education to have ovulation-inducing drugs, testing of the female, or testing of the male; 2.4 times as likely to have insemination; and 6.1 times as likely to have IVF.

¹⁸ We have done simple *t*-tests for the equality of the means across group (high/low education by age 30 and older/age under 30) and reject for all of the outcomes we examine, with *p*-values all well below 0.01.

Next we turn from the simple means to multivariate regressions. We estimate linear probability models of the form¹⁹:

$$\begin{aligned} treatment_{ist} = & \alpha + \beta_1 mandate_{st} + \beta_2 (age30+)_{ist} + \beta_3 somecoll_{ist} \\ & + \beta_4 (mandate_{st} \times age30+)_{ist} + \beta_5 (mandate_{st} \times somecoll_{ist}) \\ & + \beta_6 (age30+_{ist} \times somecoll_{ist}) + \beta_7 (mandate_{st} \times age30+_{ist} \times somecoll_{ist}) \\ & + X_{ist}\delta + Z_{st}\lambda + \gamma_s + \nu_t + \varepsilon_{ist} \end{aligned}$$

Treatment represents the treatment categories reported by NSFG respondents and described earlier. We first look at whether a woman reports ever having infertility treatment. We then break this into two groups – those who report receiving any medical help to get pregnant, and those receiving any medical help to avoid a miscarriage. (Note that these two measures are not mutually exclusive.) We then analyze the types of treatment received, looking specifically at ovulation-inducing drugs, artificial insemination, IVF, male and female testing, tubal surgery, and the residual other treatment category (treatment to get pregnant that is not one of those specific treatments listed above).

For the reasons outlined above, we expect that the mandates will have the largest impact on older, college-educated women, since they are the group at higher risk for fertility problems, and the group most likely to have private health insurance.^{20,21} Thus, our key estimated effect, β_7 , is the coefficient on the three-way interaction between the woman's state having an infertility insurance mandate, the woman's age being at least 30, and the woman having attained at least

¹⁹ All of our dependent variables are binary indicators, and some of their averages are small. One might be concerned about the use of least squares in this setting. We have verified that these results are robust to functional form by estimating the corresponding logistic regressions and calculating marginal effects. Results are quite similar in both magnitude and statistical significance and are available from authors on request.

²⁰ This group of highly-educated older women makes up about 28% of our sample or around 9,000 of the 30,149 women in our eventual sample, of whom only about 9% of our sample or about 2800 lived in states with an active mandate. It is likely that we would have been unable to detect significant effects with our empirical strategy without using all 4 waves of the NSFG. Further, without the 1982 data, we would have little or no pre-reform data for a number of the mandate-adopting states.

²¹ We cannot observe private insurance coverage in all waves of our data and likely would not want to use it as a control in any case, as it could conceivably respond to the mandates.

some college. We also control separately for mandate, age, and education effects, and all two-way interactions between mandate, age, and education. Our regressions include both state and year fixed effects.²² Finally, we look to see if there are differences in utilization effects for cover versus offer states, and for IVF versus non-IVF mandates, with the expectation that the significant effects should be larger for cover relative to offer mandates and for IVF relative to no IVF states.²³

We control for a number of individual-level characteristics, including age, race, ethnicity, educational attainment, and whether or not the woman lives in an urban area. We also control for a number of time-varying state-level characteristics, such as the share of the population that is black and the share Hispanic, the Medicaid eligibility threshold for a pregnant woman, the real maximum AFDC/TANF benefit for a family of four, real median income for a family of four, the unemployment rate, the employment growth rate, the share of the population under the Federal Poverty Level, and the share of births to unmarried women. These state-level controls have been found to be associated with fertility behavior in other work.

²² Note that if there are offsetting effects in some groups, or small effects in groups which are a larger share of the population, it might be difficult to detect these larger effects for the highly educated women when pooling all the data and identifying the policy in a differences-in-differences setting. We have examined this by estimating straight differences-in-differences regressions where the mandate variables are only allowed to vary by state and year. In these analyses, the effects for the overall population are small in magnitude compared to those reported in Tables 4 and 5 for the highly educated older women, and are statistically insignificant. We have also estimated regressions restricted to various subgroups of the population defined by age (education), where we interact the mandate with education (age). These results are all reported in an online appendix.

²³ Previous work by Bundorf, Henne and Baker (2008) and others has focused primarily on categorizing mandates as “cover including IVF” and “cover excluding IVF.” We do not use this as a primary specification due to concerns raised in a recent paper by Conley and Taber (forthcoming) about over-rejection in DD models with state level clustering when only a few states that change treatment status (only three states are cover excluding IVF states). We have estimated this as an alternate specification, and the results for ovulation-inducing drugs are significant for “cover including IVF” mandates, and slightly larger (0.03 versus 0.024) than the estimated effect for “cover excluding IVF” mandates.

We weight the data to be population-representative, and we report heteroskedasticity robust standard errors clustered at the state level.²⁴ We estimate these regressions on the sample of women who have had sex and are past menarche. We have also tested to see whether our results are driven by endogeneity of the passage of mandates by including leads of the mandate variables in our specifications; these leads are not statistically significant.

V. Results

Table 4 reports the OLS regression results for utilization of infertility treatment as a function of state-mandated infertility insurance. Column 1 replicates the findings of Bitler and Schmidt (2006) and presents results for whether the woman reported seeking any infertility treatment. These results show that the mandate itself has no statistically significant effect on reports of seeking medical help. However, the coefficient on the three-way interaction of mandate, age at least 30, and education at least some college is a positive 0.041, and is statistically significant at the 5% level. This suggests that for highly-educated older women, living in a mandate state is associated with a 4.1 percentage point increase in the probability of ever having had sought medical help to get pregnant or avoid miscarriage. The magnitude of this effect is large, given the pre-reform mean of around 15% percent of all women and 23% of more-educated women 30 and older in non-mandate states who ever sought such help.

We next break these results out between those who used medical help to get pregnant (Column 2), and those who used medical help to avoid miscarriage (Column 3). The entire effect found in Column 1 is due to those who received medical help to get pregnant – the

²⁴ The NSFG is a complex sample survey. While all waves of the NSFG used were designed to provide data that was nationally representative of the US female population 15–44, there have been numerous changes in sample design over time. In particular, different surveys oversampled different groups (e.g., black women in all NSFG waves, but Hispanic women in only 1995 and 2002, and teen women in only 1982). As a result, we use the population weights provided by the NSFG to ensure the results are population representative.

estimated coefficient on the 3-way interaction is similar in both magnitude and statistical significance to the original coefficient. The estimated effect of the 3-way interaction on help to avoid miscarriage is much smaller in magnitude and not statistically different from zero.²⁵ Another way to get a sense of the magnitude of these effects is to normalize them by the baseline mean, which translates them into a percent increase from the baseline. The bottom two rows of the table report the baseline mean of the relevant dependent variable for more-educated women 30 and older in no mandate states and the three way interaction effect measured as a share of this baseline. This suggests that the estimated effects of the mandates on older, educated women are considerably larger as a share of the baseline for medical help to get pregnant (24%) compared to medical help to avoid miscarriage (8%). This is as expected – the miscarriage variable should respond only indirectly to the mandates (e.g., if women who use infertility treatment conceive but are more likely to miscarry), so any effect of infertility insurance mandates on the miscarriage help variable should be smaller in magnitude than the effect on help to get pregnant.

The two-way mandate interactions in Column 2 (mandate \times 30 and older, mandate \times some college) are negative and statistically significant, which may be surprising, given that the mandate should lower costs for anyone affected by the mandate.²⁶ However, even a variable like “ever sought medical help to get pregnant” includes a wide variety of treatments, some of which may be less relevant in the presence of mandates (for example, tubal surgery). Thus, we also explore the use of specific treatments in Table 5.

²⁵ The magnitude of these coefficients is quite different as well. The effect on medical help to get pregnant is larger in magnitude, and the coefficient’s 95% CI is [0.009, 0.072] which excludes the point estimate for medical help to prevent miscarriage. Similarly, the upper bound for the 95% CI for the miscarriage variable coefficient excludes the coefficient on help to get pregnant. We cannot perform a seemingly unrelated regression test, since women may report medical help to get pregnant or medical help to avoid miscarriage, or both.

²⁶ We also explore regressions restricted to age and education subgroups (reported in online appendix Tables 3 and 4), to be sure that our significant results are not being driven by these negative effects for some subgroups one might expect not to be affected. Results are discussed in the online appendix.

In Table 5, we look separately at different types of infertility treatments: use of ovulation-inducing drugs, use of artificial insemination, use of IVF, testing (separately by testing of the female and of the male), tubal surgery, and some other treatment. Recall from Section III that most individuals who receive infertility proceed through a hierarchical process. Therefore, most individuals who receive ARTs like IVF will have already received lower level treatments such as ovulation-inducing drugs.²⁷ The estimated coefficient for β_7 , our key variable of interest, is positive and statistically significant for the use of ovulation-inducing drugs, suggesting that mandates led to a 2 percentage point increase in use of these drugs for older women with some college. This coefficient is not statistically different from the coefficients on testing of either the male or female (neither of which is significant), which also suggest in each case an effect of the mandates among older college-educated women of nearly 2 percentage points. However, the effect of mandates on use of ovulation-inducing drugs for older, educated women is considerably larger as a share of pre-mandate use than the effect on testing. A 2 percentage point increase in use of ovulation-inducing drugs with mandates reflects a 32% increase from a baseline level of use of 6.2 percent of women 30 and older with some college, compared to a 24% increase in the use of testing for females or males from a baseline level of use of 7.5 percent for female testing or 6.8 percent for male testing.

These effects are quite large in magnitude as a share of pre-mandate means. However, evidence suggests that unmet demand for infertility treatments in the United States is quite large. For example, in some European countries, where the government is much more likely to cover infertility treatment, utilization rates for ARTs are considerably higher than in the US. Andersen et al. (2008) report that ART procedures in Denmark were associated with 4.2% of live births in

²⁷ As noted earlier and shown in Table 2, this is empirically the case in our data, as many who obtain one treatment get others as well.

2004, compared to about 1.2% in the US (Martin, Hamilton, et al., 2006; Wright, Chang, et al., 2007). A Centers for Disease Control FAQ about infertility reports that 20% of women have their first child while 35 or older, and notes that among couples where the woman is over 35, one-third face an infertility problem (<http://www.cdc.gov/reproductivehealth/Infertility/>). Connolly et al. (2009) use the introduction of a 50% copay for patients in Germany to estimate a price elasticity of demand, using a pre-post design. They find an elasticity for IVF of -0.36. Taken together, this evidence suggests that coverage of these expensive therapies could lead to substantive increases in demand.²⁸

Turning to the rest of the specific treatments, we note that while not significant, the effect for artificial insemination is also positive and large as a share of the baseline. Use of IVF is not estimated to increase, but so few women report use of IVF in the NSFG that it would be surprising if we were able to discern any effects. In addition, the mandates have a small negative effect on the probability that a woman reports tubal surgery (although this effect is not statistically different from zero). It is plausible that there could be little change or even a decrease in tubal surgeries. First, evidence suggests that under an insurance plan that specifically excluded infertility treatment, non-negligible fractions of claims paid for certain tubal and other surgeries were actually infertility related (Blackwell and Mercer, 2000; Jones and Allen, 2009).²⁹ Secondly, as mentioned above, some evidence suggests that IVF and tubal surgeries could be seen as somewhat substitutable (Gocial, 1995; Practice Committee of the ASRM, 2008).

²⁸ Our findings cannot tell us whether mandates hasten fertility for women who would have children anyways; allow women to conceive who would not be able to otherwise; or create a form of moral hazard, where they encourage women to wait longer to start trying to conceive, relying on infertility treatment as insurance. We would love to answer these questions, but despite the many advantages of the NSFG data, they do not have information on when women start trying to conceive, or how long they had treatment, or whether the treatment itself resulted in a live birth.

²⁹ For example, the firm paid a small amount of claims for the procedure transcervical fallopian tube catheterization (CPT code 58345) which was estimated by Blackwell and Mercer to be 100% for infertility treatment despite the fact that the firm did not cover infertility treatment.

The regressions on specific treatments also provide some insight into the negative and significant two-way interactions in Table 4. None of the two-way interactions for expensive treatments that are difficult to have reimbursed in the absence of infertility coverage are significant at the 5 percent level. The negative statistically significant “mandate \times 30 and older” effect seen in Table 4, Column 2 for any medical help to get pregnant is entirely driven by a decrease in the residual category of other treatment. The negative “mandate \times some college” effect from Table 4 for medical help to get pregnant is associated with a small decrease in ovulation-inducing drugs (only significant at the 10% level), and a slightly larger decrease in male testing (significant at the 1% level).

As described above, the mandates differ along several dimensions. First, some mandates require that infertility treatments be covered, while others only require that coverage be offered. In Panel A of Tables 6 and 7, we break out cover mandates from offer mandates. Focusing first on Column 2 of Table 6, the broad indicator of whether a woman received any medical help to get pregnant shows similar effects of cover and offer mandates on utilization of services – the estimated coefficients are not statistically different between the two types of regressions. For the IVF versus no-IVF mandates, the mandates that include IVF have an effect that is twice the magnitude than the mandates that exclude it (although the coefficients are not statistically different - the F -statistic for the two coefficients being the same is 1.14, with a p -value of 0.291 for the two-sided test and 0.146 for the one sided test that the IVF coefficient is smaller than the no-IVF coefficient).

However, the estimated effects of the different types of mandates are more striking when we examine the more detailed breakdown of treatments by type, in Table 7. The estimated coefficients of cover mandates on ovulation-inducing drugs, artificial insemination, and testing

of the female are positive and statistically significant. Cover mandates have a larger effect than do offer mandates on the more expensive treatments of ovulation-inducing drugs (F -statistic is 1.77, p -value of 0.189 for two-sided test and 0.095 for the one sided test that the cover coefficient is smaller than the offer coefficient), and artificial insemination (F -statistic is 3.03, p -value of 0.088 for the two-sided test and 0.044 for the one sided test). The significant effects for the offer mandates seen in Table 7 come entirely from the residual other treatment category.³⁰ In Panel B, we break out mandates that include IVF from those that do not. Again, IVF mandates have a statistically significant and positive effect on ovulation-inducing drugs. While the point estimate for the IVF mandates is usually larger than that for the no IVF mandates, the coefficients are not statistically different from each other (even with one-sided tests). Again, we estimate no impact on IVF, but this is likely a consequence of the small numbers of women reporting IVF in our population data.

VI. Robustness

We have also estimated a number of robustness tests, including specifications with leads, specifications where mandate variables are allowed to vary by time since implementation, and specifications estimated on various subsamples. Some of these results are available in an on-line appendix, while others are available on request. In general, the effects are consistent with our main results in Tables 4-5, with largest effects for ovulation-inducing drugs and artificial insemination.

VII. Discussion and Conclusion

³⁰ One possibility is that in offer states, women receive advice, but then realize they are not covered for more expensive treatments, and as a result stop at that point.

Previous evidence concerning the effect of various health insurance mandates suggests many such mandates have little impact on health care utilization. In this paper, we pool data from waves of the National Survey of Family Growth to see whether mandates for infertility treatment affect use of infertility treatment among women 15–44. Our results suggest that state-level mandates related to coverage of infertility treatment are associated with a substantial and statistically significant increase in utilization of services, with effects largest among a subgroup of older, more-educated women. Among specific types of infertility treatments, we find the largest effects on ovulation-inducing drugs and artificial insemination.

These findings provide some of the only evidence available about use of non-ART infertility treatments. In addition, they provide evidence on population use of treatments, and unlike recent work examining fertility, they include effects for women who may never successfully have children. For example, of the women in the NSFG who obtained any medical help to get pregnant, fully 28% of all women and 25% of the older highly-educated women had no first birth after their first infertility visit. These fractions provide a possible upper bound on the share of women who do not succeed in having a live birth despite their use of treatment.³¹

One potential concern with the results presented above is that the mandates could be correlated with broader trends in fertility, and that our estimated mandate effects could therefore be picking up these broader trends. Our results suggest that, as expected, the mandates have the greatest effect on the more expensive and less easily hidden types of treatment, and that help to

³¹ Some of these women with no first birth are likely in the middle of treatment, and may yet have a child. This is an upper bound on the share of women who are unsuccessful despite obtaining infertility treatment. If we limit this calculation to those women who had no first birth after their first infertility treatment and have not had a visit for infertility treatment in the past year, assuming that these women might be the most likely to have given up trying to conceive, we see that 14% of all women and 15% of the older educated women fall into this category. Of the remaining women, 43% of all women and 46% of the older, more-educated women had a first birth after their first visit; and 29% of both sets of women had already had a first birth before the first visit, and may therefore have been seeking treatment for secondary infertility. We can not tell what the outcomes are for the women with any first birth before their first visit. We have not further examined these timing variables, as they are only reported in the last 2 waves of the NSFG.

prevent miscarriage is largely unaffected by the mandates. Both of these findings lend confidence to our interpretation of the results.

One implication of our findings is that subgroup heterogeneity is likely to be important when analyzing the utilization and health impacts of various health insurance mandates. This is particularly true given that most health insurance mandates only apply to a share of private-sector employees. Since mandates are enacted to affect utilization of services and, ultimately, health outcomes, understanding why certain mandates affect these variables is important for policy efficacy. One possible explanation for our findings of a utilization effect, when few of these effects have been found in the broader mandate literature, is that in the case of infertility treatment, those individuals who are most likely to demand services (women who are older and highly-educated) are also most likely to be affected by the mandate due to their higher probability of having private health insurance. For many other mandates, these two populations may not be the same. In those cases, affecting health outcomes may require other policy interventions.

References

- Acs, Gregory, Stephen H. Long, M. Susan Marquis, and Pamela Farley Short. 1996. "Self-Insured Employer Health Plans: Prevalence, Profile, Provisions, and Premiums." *Health Affairs* 15(2): 266–278.
- Agency for Healthcare Research and Quality, Center for Financing, Access and Cost Trends. 2005. "2003 Medical Expenditure Panel Survey-Insurance Component Table II.D.1(2003) Average Total Family Premium (in dollars) per enrolled employee at private-sector establishments that offer health insurance by firm size and state: United States, 2003." Web publication available at http://www.meps.ahrq.gov/MEPSDATA/ic/2003/Tables_II/TIID1.pdf.
- American Society of Reproductive Medicine. 2003. *Patient Fact Sheet: Frequently Asked Questions About Infertility*.
- Anderson, John E., Sherry L. Farr, Denise J. Jamieson, Lee Warner, and Maurizio Macaluso. 2009. "Infertility Services Reported by Men in the United States: National Survey Data." *Fertility and Sterility* 91(6): 2466-2470.
- Andersen, A.N., Goosens, V., Ferraretti, et al. 2008. "Assisted Reproductive Technology in Europe, 2004: Results Generated from European Registers by ESHRE." *Human Reproduction*, 1-16.
- Ananat, Elizabeth Oltmans, Jonathan Gruber, and Phillip B. Levine. 2007. "Abortion Legalization and Lifecycle Fertility." *Journal of Human Resources* 42(2): 375-397.
- Bailey, Martha J. 2006. "More Power to the Pill: The Impact of Contraceptive Freedom on Women's Lifecycle Labor Supply." *Quarterly Journal of Economics* 121(1): 289-320.
- Bao, Yuhua and Roland Sturm. 2004. "The Effects of State Mental Health Parity Legislation in Perceived Quality of Insurance Coverage, Perceived Access to Care, and Use of Mental Health Specialty Care." *Health Services Research* 39(5): 1361.
- Bitler, Marianne. 2010. Effects of Increased Access to Infertility Treatment on Infant and Child Health Outcomes: Evidence from Health Insurance Mandates. Mimeo.
- Bitler, Marianne and Christopher Carpenter. 2009. Insurance Mandates and Mammography. Mimeo.
- Bitler, Marianne and Lucie Schmidt. 2006. "Health Disparities and Infertility: Impacts of State-Level Insurance Mandates." *Fertility and Sterility* 85(4): 858–865.
- Blackburn, McKinley L., David Bloom and David Neumark. 1993. "Fertility Timing, Wages, and Human Capital." *Journal of Population Economics* 93: 1–30.

- Blackwell, Richard and Team, William M. Mercer Actuarial. 2000. "Hidden Costs of Infertility Treatment in Employee Health Benefits Plans." *American Journal of Obstetrics and Gynecology* 182:4.
- Buckles, Kasey. 2006. "Stopping the Biological Clock: Fertility Therapies and the Career/Family Tradeoff." Mimeo.
- Bundorf, M. Kate, Natalie Chun, Gopi Shah Goda, and Daniel P. Kessler. 2009. "Do Markets Respond to Quality Information? The Case of Fertility Clinics." *Journal of Health Economics* 28: 718–727.
- Bundorf, M. Kate, Melinda Henne, and Laurence Baker. 2008. "Mandated Health Insurance Benefits and the Utilization and Outcomes of Infertility Treatment." NBER Working Paper 12820.
- Chambers, Georgina M., Elizabeth A. Sullivan, Osamu Ishihara, Michael G. Chapman, and G. David Adamson. 2009. "The Economic Impact of Assisted Reproductive Technology: a Review of Selected Developed Countries." *Fertility and Sterility* 91(6): 2281–2294.
- Chandra Anjani and Elizabeth Hervey Stephen. 2005. Infertility and Medical Care for Infertility: Trends and Differentials in National Self-Reported Data, Presentation at NIH Conference on Health Disparities and Infertility, March 10–11, 2005.
- Collins, John. 2001. "Cost-Effectiveness of IVF." *Seminars in Reproductive Medicine* 19: 279–289.
- Conley, Timothy and Christopher Taber. Forthcoming. "Inference with 'Differences in Differences' with a Small Number of Policy Changes." *Review of Economics and Statistics*.
- Connolly, M.P., Griesinger, G., Ledge, W. and Postma, M. J. 2009. "The Impact of Introducing Patient Co-Payments in Germany on the Use of IVF and ICSI: A Price Elasticity of Demand Assessment." *Human Reproduction* 24(11): 2796-2800.
- Employee Benefit Research Institute. 2005. *Fundamentals of Employee Benefit Programs*. Washington, D.C.
- Gabel, Jon, Gail A. Jensen, and Samantha Hawkins. 2003. "Self-Insurance in Times of Growing and Retreated Managed Care." *Health Affairs* 22(2): 202–210.
- Gelbach, Jonah B., Jonathan Klick, and Lesley Wexler. Forthcoming. "Passive Discrimination: When Does It Make Sense to Pay Too Little?" *University of Chicago Law Review*.
- Gleicher N. 2000. "Cost-Effective Infertility Care." *Human Reproduction Update* 6(2): 190–199.

- Gocial, B. 1995. "Primary Therapy for Tubal Disease: Surgery Versus IVF." *International Journal of Fertility and Menopausal Studies*. 40(6): 297–302.
- Goldin, Claudia and Lawrence T. Katz. 2002. "The Power of the Pill: Oral Contraceptives and Women's Career and Marriage Decisions." *Journal of Political Economy* 110(4): 730–70.
- Gruber, Jonathan. 1994. "State-Mandated Benefits and Employer-Provided Health Insurance." *Journal of Public Economics* 55: 433–464.
- Guldi, Melanie. 2008. "Fertility Effects of Abortion and Birth Control Pill Access for Minors." *Demography* 48(3): 817–827.
- Hamilton, Barton and Brian McManus. 2004. "Infertility Treatment Markets: The Effects of Competition and Policy." Mimeo.
- Henne, Melinda B. and M. Kate Bundorf. 2008. "Insurance Mandates and Trends in Infertility Treatments." *Fertility and Sterility* 89(1): 66-73.
- Jain, Tarun, Bernard L. Harlow, and Mark D. Hornstein. 2002. "Insurance Coverage and Outcomes of In Vitro Fertilization." *New England Journal of Medicine* 347(9): 661–666.
- Jensen, Gail A., Kathryn Rost, Russell P.D. Burton, and Maria Bulycheva. 1998. "Mental Health Insurance in the 1990s: Are Employers Offering Less to More?" *Health Affairs* 17(3): 201–208.
- Jones, Howard W. Jr. and Brian D. Allen. 2009. "Strategies for Designing an Efficient Insurance Fertility Benefit: a 21st Century Approach." *Fertility and Sterility* 91(6): 2295–2297.
- Kaestner, Robert and Kosali Ilayperuma Simon. 2002. "Labor Market Consequences of State Health Insurance Regulation." *Industrial and Labor Relations Review* 56(1): 136–159.
- Liu, Zhimei, William H. Dow, and Edward C. Norton. 2004. "Effect of Drive-Through Delivery Laws on Postpartum Length of Stay and Hospital Charges." *Journal of Health Economics* 23: 129–155.
- Martin, J.A., Hamilton, B.E., et al. 2006. *Births: Final Data for 2004*. National Vital Statistics Reports 55:1.
- Mathews, T.J. and Brady E. Hamilton. 2002. "Mean Age of Mother: 1970–2000." National Vital Statistics Reports 51(1). Hyattsville, Maryland: National Center for Health Statistics.
- Menken, Jane. 1985. "Age and Fertility: How Late Can You Wait?" *Demography* 22(4): 469–483.

- Miller, Amalia R. 2008. "The Effects of Motherhood Timing on Career Path." Mimeo.
- Mookim, Pooja G., Randall P. Ellis, and Ariella Kahn-Lang. 2008. "Infertility Treatment, ART and IUI Procedures and Delivery Outcomes: How Important is Selection?" Mimeo.
- Neumann PJ, Gharib SD, and Weinstein, MC. 1994. "The Cost of a Successful Delivery with In Vitro Fertilization." *New England Journal of Medicine* 331(4): 239–43.
- New York Times*. September 1, 2001. "Insurers Offering Pregnancy Benefits Now Must Cover Fertility."
- Oyer, Paul. Forthcoming. "Salary or Benefits?" *Research in Labor Economics*.
- Pacula, Rosalie Liccardo and Roland Sturm. 2000. "Mental Health Parity Legislation: Much Ado About Nothing." *Health Services Research* 35: 263–275.
- Practice Committee of the American Society of Reproductive Medicine. 2008. "The Role of Tubal Reconstructive Surgery in the Era of Assisted Reproductive Technologies." *Fertility and Sterility* 90 (Supplement 3): S250-S253).
- RESOLVE. 2003. Insurance Coverage of Infertility Treatments, Bethesda MD: RESOLVE: The National Infertility Association.
- Rothschild, Michael and Joseph E. Stiglitz. 1976. "Equilibrium in Competitive Insurance Markets: An Essay on the Economics of Imperfect Information." *Quarterly Journal of Economics* 90(4): 629–49.
- Schmidt, Lucie. 2007. "Effects of Infertility Insurance Mandates on Fertility." *Journal of Health Economics* 26(3): 431–446.
- Schmidt, Lucie. 2005. "Effects of Infertility Insurance Mandates on Fertility." Williams College Unpublished Mimeo.
- Stephen, Elizabeth Hervey and Anjani Chandra. 2000. "Use of Infertility Services in the United States: 1995" *Family Planning Perspectives* 32(3): 132–137.
- Weinstein, Maxine, James W. Wood, Michael A. Stoto, and Daniel D. Greenfield. 1990. "Components of Age-Specific Fecundability." *Population Studies* 44: 447–467.
- William M. Mercer Company. 1997. *Women's Health Issues: Infertility as a Covered Benefit*.
- Wright, Victoria C., Laura A. Schieve, Meredith A. Reynolds, and Gary Jeng. 2003. "Assisted Reproductive Technology Surveillance—United States 2000. MMWR Surveillance Summaries. 52(SS09): 1–16.

Wright, V.C., Chang, J., Jeng, G., Chen, M., and Macaluso, M. "Assisted Reproductive Technology Surveillance-United States, 2004." *MMWR Surveillance Summaries* 56:SS06, 2007, 1-22.

Table 1: States with Mandated Infertility Insurance

State	Year law enacted	Mandate to cover/offer to cover	IVF covered?
Arkansas	1987 ^a	Cover	Yes
California	1989	Offer	No
Connecticut	1989 ^b	Offer	Yes
Hawaii	1987	Cover	Yes
Illinois	1991	Cover	Yes
Louisiana	2001	Cover	No
Maryland	1985	Cover	Yes
Massachusetts	1987	Cover	Yes
Montana	1987	Cover	Yes
New Jersey	2001	Cover	Yes
New York	1990 ^c	Cover	No
Ohio	1990 ^d	Cover	Yes
Rhode Island	1989	Cover	Yes
Texas	1987	Offer	Yes
West Virginia	1977 ^e	Cover	No

Source: Schmidt (2007).

^a Some coverage for IVF was first required in 1987. The law was revised in 1991 to set maximum and minimum benefit levels and to establish standards for determining whether a policy or certificate must include coverage (see Appendix A of Schmidt (2005)).

^b In 2005, Connecticut changed their offer mandate to a cover mandate.

^c In 2002, New York passed a revised law that clarified the 1990 legislation and appropriated \$10 million to a pilot project to help pay for IVF for a small number of individuals.

^d The original 1991 law did not specifically exclude IVF but in 1997 the state Superintendent of Insurance stated that IVF, GIFT, and ZIFT were not essential for the protection of an individual's health and were therefore not subject to mandated coverage. We code Ohio as an IVF state through 1997.

^e In 2001, the law was amended to mandate that HMOs must cover infertility treatment only as a "preventative service" benefit (thus, excluding IVF).

Table 2: Share of women obtaining one treatment who had each of the other treatments, all women, pooled NSFG data

	Ovulation inducing drugs	Artificial insemination	IVF	Testing of female	Testing of male	Tubal surgery	Any other treatment	Other treatment and not 1–6
<i>A. Share of women in row group getting treatment</i>								
All women	0.034	0.008	0.002	0.039	0.035	0.013	0.076	0.038
Women who got help to get pregnant	0.337	0.081	0.017	0.388	0.351	0.126	0.763	0.377
<i>B. Share of women getting column treatment who also used:</i>								
Ovulation inducing drugs	1	0.71	0.65	0.54	0.49	0.49	0.30	0
Artificial insemination	0.17	1	0.46	0.18	0.17	0.17	0.08	0
IVF	0.03	0.10	1	0.04	0.04	0.06	0.02	0
Testing of female	0.62	0.85	0.80	1	0.75	0.62	0.36	0
Testing of male	0.52	0.75	0.79	0.68	1	0.53	0.34	0
Tubal surgery	0.18	0.27	0.42	0.20	0.19	1	0.11	0
Any other treatment	0.69	0.78	0.78	0.70	0.74	0.69	1	1
Other treatment, not rows 1–6	0	0	0	0	0	0	0.48	1

Notes: Shown are weighted averages among various samples of women who have ever had sex after menarche for various outcomes. Panel A contains the share of the women in the row sample who obtained the treatments in the column headings. Panel B contains the share of women getting the treatment in the column heading who also got the treatment in the row label. Treatments are not mutually exclusive (with the exception of the last row/column “other treatment none of the specific ones” which is mutually exclusive with the specific treatments). The “other treatments” in some years includes advice on timing sex or timing use of birth control or other advice and other surgeries (e.g., fibroids). Data are from pooled 1982, 1988, 1995, and 2002 waves of the NSFG. Rounding for various rows done independently.

Table 3: Summary statistics for use of infertility treatment and fertility outcomes, all women and by group, pooled NSFG data

	All		Age under 30		Age 30 and older	
	Women	No college	Some college	No college	Some college	Some college
Ever had any infertility treatment (to get pregnant or prevent miscarriage)	0.145 (0.002)	0.073 (0.005)	0.088 (0.004)	0.162 (0.004)	0.228 (0.004)	0.228 (0.004)
Ever had treatment to help get pregnant	0.100 (0.002)	0.048 (0.003)	0.048 (0.004)	0.112 (0.003)	0.168 (0.003)	0.168 (0.003)
Ever had treatment to prevent miscarriage	0.068 (0.001)	0.048 (0.003)	0.033 (0.003)	0.073 (0.003)	0.103 (0.003)	0.103 (0.003)
<i>Type of treatments to help get pregnant (not mutually exclusive)</i>						
Ovulation-inducing drugs	0.034 (0.001)	0.014 (0.002)	0.014 (0.002)	0.034 (0.002)	0.065 (0.002)	0.065 (0.002)
Artificial insemination	0.008 (0.001)	0.001 (0.001)	0.002 (0.001)	0.008 (0.001)	0.019 (0.001)	0.019 (0.001)
In vitro fertilization	0.002 (0.0002)	0.0002 (0.0005)	0.0002 (0.0005)	0.0008 (0.0004)	0.0049 (0.0004)	0.0049 (0.0004)
Woman tested for infertility	0.039 (0.001)	0.013 (0.002)	0.013 (0.003)	0.040 (0.002)	0.077 (0.002)	0.077 (0.002)
Man tested for infertility	0.035 (0.001)	0.014 (0.002)	0.011 (0.002)	0.036 (0.002)	0.069 (0.002)	0.069 (0.002)
Surgery to correct blocked Fallopian tubes	0.013 (0.001)	0.005 (0.001)	0.003 (0.001)	0.016 (0.001)	0.023 (0.001)	0.023 (0.001)
Some other treatment	0.038 (0.001)	0.023 (0.002)	0.023 (0.003)	0.044 (0.002)	0.055 (0.002)	0.055 (0.002)
Private insurance paid for treatment†	0.070 (0.002)	0.020 (0.004)	0.030 (0.005)	0.073 (0.004)	0.126 (0.003)	0.126 (0.003)
No private insurance to pay for treatment†	0.023 (0.001)	0.015 (0.002)	0.007 (0.003)	0.025 (0.002)	0.035 (0.002)	0.035 (0.002)
N	30,149	11,328	6182	8973	8425	8425

Notes: Shown are weighted averages among women who have ever had sex after menarche for various outcomes. The means are for the sample of women described in the column labels. Only women who reported getting medical help to get pregnant are asked about the types of treatment they received. Treatments are not mutually exclusive. Other treatment in some years includes advice on timing sex or timing use of birth control or other advice. Data are from pooled 1982, 1988, 1995, and 2002 waves of the NSFG. Rounding for various rows done independently. † Questions on how they paid for the medical help to get pregnant are only asked in the 1995 and 2002 waves of the NSFG.

Table 4: Determinants of any infertility treatment, medical help to get pregnant, and medical help to avoid miscarriage

	Any infertility treatment	Medical help to get pregnant	Medical help to avoid miscarriage
Any mandate	0.007 (0.011)	0.004 (0.010)	0.002 (0.007)
Age 30 and older	0.079*** (0.007)	0.072*** (0.007)	0.022*** (0.005)
Some college	-0.016** (0.007)	-0.0001 (0.005)	-0.015*** (0.005)
Mandate * 30 and older	-0.021 (0.013)	-0.027** (0.010)	0.003 (0.009)
Mandate * some college	-0.013 (0.009)	-0.015** (0.007)	-0.004 (0.008)
30 and older * some college	0.071*** (0.012)	0.046*** (0.010)	0.043*** (0.008)
Mandate * >= 30 * some college	0.041** (0.018)	0.041** (0.016)	0.008 (0.013)
Mean, no mandate in effect, women >= 30 & some college	0.228	0.170	0.100
3 way interaction as share of mean	0.18	0.24	0.08

Notes: Shown are coefficients from least squares regressions of the determinants of ever having had various types of infertility treatments. Each column presents results from a single regression. Regressions are weighted, with standard errors clustered at the state level in parentheses. Specifications include state and year of interview fixed effects and individual demographic and state-by-year level demographic, policy, and economic controls. Data are from pooled 1982, 1988, 1995, and 2002 waves of the NSFG. Sample is all women who ever had sex after menarche. ***, **, and * denote significance of the coefficient at the 1, 5, and 10 percent levels. Bottom two rows present pre-mandate mean of dependent variable for women ≥ 30 and the 3 way interaction effect (coefficient on mandate * $>= 30$ * some college) as a share of the baseline mean.

Table 5: Determinants of specific medical treatments to help get pregnant

	Ovulation inducing drugs	Artificial insemination	IVF	Testing of female	Testing of male	Tubal surgery	Other Treatment
Any mandate	0.001 (0.004)	-0.0001 (0.0029)	0.0008 (0.0012)	-0.005 (0.006)	-0.003 (0.006)	0.0003 (0.0028)	0.005 (0.008)
Age 30 and older	0.020*** (0.003)	0.006*** (0.001)	0.0004 (0.0006)	0.027*** (0.004)	0.022*** (0.004)	0.010*** (0.002)	0.026*** (0.006)
Some college	-0.002 (0.003)	-0.0006 (0.0012)	-0.0005 (0.0003)	-0.004 (0.003)	-0.004 (0.003)	-0.003 (0.002)	0.001 (0.003)
Mandate * 30 and older	-0.004 (0.005)	-0.0005 (0.0027)	0.0002 (0.0006)	-0.008 (0.007)	-0.002 (0.007)	0.0002 (0.0029)	-0.013** (0.006)
Mandate * some college	-0.008* (0.004)	-0.001 (0.002)	0.0011 (0.0010)	-0.007 (0.005)	-0.010*** (0.004)	-0.001 (0.002)	-0.002 (0.005)
30 and older * some college	0.026*** (0.005)	0.008*** (0.003)	0.0041*** (0.0011)	0.033*** (0.006)	0.032*** (0.006)	0.010*** (0.003)	0.008 (0.007)
Mandate * >= 30 * some college	0.020** (0.009)	0.007 (0.005)	-0.00002 (0.00216)	0.018 (0.013)	0.016 (0.011)	-0.002 (0.006)	0.011 (0.009)
Mean, no mandate in effect,, women >= 30 & some college	0.062	0.017	0.005	0.075	0.068	0.024	0.057
3 way interaction as share of mean	0.32	0.41	-0.004	0.24	0.24	-0.08	0.19

Notes: Shown are coefficients from least squares regressions of the determinants of ever having had various types of infertility treatments. Results in column 6 for outcome “other treatment” are for some other treatment besides the ones in columns 1–6. Each column presents results from a single regression. Regressions are weighted, with standard errors clustered at the state level in parentheses. Specifications include state and year of interview fixed effects and individual demographic and state-by-year level demographic, policy, and economic controls. Data are from pooled 1982, 1988, 1995, and 2002 waves of the NSFG. Sample is all women who ever had sex after menarche. ***, **, and * denote significance of the coefficient at the 1, 5, and 10 percent levels. Bottom two rows present pre-mandate mean of dependent variable for women ≥ 30 and the 3 way interaction effect (coefficient on mandate * $>= 30$ * some college) as a share of the baseline mean.

Table 6: Determinants of any infertility treatment, medical help to get pregnant, and medical help to avoid miscarriage, by type of mandate

	Any infertility treatment	Medical help to get pregnant	Medical help to avoid miscarriage
<i>A. Mandate varies by whether mandate is to cover or offer</i>			
Cover mandate * $>= 30$ * some college	0.055** (0.027)	0.040 (0.024)	0.027* (0.015)
Offer mandate * $>= 30$ * some college	0.026* (0.014)	0.043*** (0.014)	-0.014 (0.009)
<i>F</i> -statistic, test coefficients equal	1.25 (0.269)	0.02 (0.900)	8.95 (0.004)
<i>p</i> -value, 2 sided test	[0.135]	[0.550]	[0.002]
<i>p</i> -value, 1 sided test, null cover less than offer			
<i>B. Mandate varies by whether IVF is excluded or not</i>			
Mandate with IVF * $>= 30$ * some college	0.049** (0.021)	0.052*** (0.015)	0.016 (0.020)
Mandate no IVF * $>= 30$ * some college	0.030 (0.025)	0.028 (0.022)	-0.002 (0.016)
<i>F</i> -statistic, test coefficients equal	0.46 (0.499)	1.14 (0.291)	0.62 (0.435)
<i>p</i> -value, 2 sided test	[0.250]	[0.146]	[0.218]
<i>p</i> -value, 1 sided test, null IVF less than no IVF			

Notes: Shown are coefficients from least squares regressions of the determinants of ever having had various types of infertility treatments. Each panel contains results with a different set of mandate education age interactions. Each column within panel presents results from a single regression. At bottom of panel, *F*-tests for equality of the coefficients shown are reported, along with *p*-values from two-sided tests in parentheses and the *p*-values from a one-sided test of the null that the cover coefficient is less than the offer coefficient (panel A) or the null that the IVF-allowed coefficient is less than the no-IVF coefficient (panel B), in brackets. Regressions are weighted, with standard errors clustered at the state level in parentheses. Specifications include state and year of interview fixed effects and individual demographic and state-by-year level demographic, policy, and economic controls. Data are from pooled 1982, 1988, 1995, and 2002 waves of the NSFG. Sample is all women who ever had sex after menarche. ***, **, and * denote significance of the coefficient at the 1, 5, and 10 percent levels.

Table 7: Determinants of specific medical treatments to help get pregnant, by type of mandate

	Ovulation inducing drugs	Artificial insemination	IVF	Testing of female	Testing of male	Tubal surgery	Other Treatment
<i>A. Mandate varies by whether mandate is to cover or offer</i>							
Cover mandate * ≥ 30 *	0.030** (0.014)	0.012* (0.006)	0.001 (0.003)	0.034* (0.017)	0.025 (0.016)	-0.0002 (0.0057)	-0.005 (0.009)
some college							
Offer mandate * ≥ 30 *	0.009 (0.009)	0.0006 (0.0048)	-0.001 (0.001)	-0.0005 (0.0067)	0.005 (0.007)	-0.003 (0.008)	0.029*** (0.007)
some college							
F-statistic, test coefficients equal	1.77 (0.189)	3.03 (0.088)	0.47 (0.495)	4.35 (0.042)	1.77 (0.189)	0.13 (0.722)	18.96 (0.0001)
p-value, 2 sided test	[0.095]	[0.044]	[0.248]	[0.021]	[0.095]	[0.361]	[0.99997]
p-value, 1 sided test, null cover less than offer							
<i>B. Mandate varies by whether IVF is excluded or not</i>							
Mandate with IVF* ≥ 30 *	0.028*** (0.010)	0.005 (0.007)	-0.0006 (0.003)	0.018 (0.014)	0.021 (0.013)	0.002 (0.004)	0.013 (0.010)
some college							
Mandate no IVF * ≥ 30 *	0.011 (0.013)	0.008 (0.005)	0.0007 (0.0018)	0.015 (0.018)	0.010 (0.013)	-0.006 (0.008)	0.009 (0.023)
some college							
F-statistic, test coefficients equal	1.02 (0.318)	0.18 (0.672)	0.14 (0.711)	0.02 (0.902)	0.45 (0.503)	1.35 (0.250)	0.06 (0.814)
p-value, 2 sided test	[0.159]	[0.664]	[0.645]	[0.451]	[0.252]	[0.125]	[0.407]
p-value, 1 sided test, null IVF less than no IVF							

Notes: Shown are coefficients from least squares regressions of the determinants of ever having had various types of infertility treatments. Each panel contains results with a different set of mandate education age interactions. Each column within panel presents results from a single regression. At bottom of panel, F -tests for equality of the coefficients shown are reported, along with p -values from two-sided tests in parentheses and the p -values from a one-sided test of the null that the cover coefficient is less than the offer coefficient (panel A) or the null that the IVF-allowed coefficient is less than the no-IVF coefficient (panel B), in brackets. Regressions are weighted, with standard errors clustered at the state level in parentheses. Specifications include state and year of interview fixed effects and individual demographic and state-by-year level demographic, policy, and economic controls. Data are from pooled 1982, 1988, 1995, and 2002 waves of the NSFG. Sample is all women who ever had sex after menarche. ***, **, and * denote significance of the coefficient at the 1, 5, and 10 percent levels.